Agios Pharmaceuticals traded at $27.99 this Friday May 15th, decreasing $0.74 or 2.58 percent since the previous trading session. Looking back, over the last four weeks, Agios Pharmaceuticals lost 19.85 percent. Over the last 12 months, its price fell by 4.08 percent. Looking ahead, we forecast Agios Pharmaceuticals to be priced at 27.21 by the end of this quarter and at 25.56 in one year, according to Trading Economics global macro models projections and analysts expectations.
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.